← Back to patent-cliff list
Zeta-BC-003
Tier C — Watch / tradeZeta-BC-003
Zetagen Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Brand：ZetaFuse, ZetaMet
Indications (approved)：Metastatic breast cancer, 神经疾病, 椎间盘退化
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zeta-BC-003?
Approved indications include: Metastatic breast cancer, 神经疾病, 椎间盘退化.
When does the Zeta-BC-003 patent expire?
No public expiry year is available for Zeta-BC-003 yet; this page updates once verified.
How do I get a quote for Zeta-BC-003 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05